AZ Rides PACIFIC Wave To Be First In Early-Stage NSCLC

After Imfinzi's failure in the MYSTIC trial, AstraZeneca is very much back in the lung cancer game following the success of the PACIFIC study.

Surfing
AstraZeneca stays afloat in I-O after strong data for Imfinzi • Source: Shutterstock

More from Immuno-oncology

More from Anticancer